Di Brizzi, E.V. (2024) “Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?”, Dermatology Practical & Conceptual, 14(4), p. e2024284. doi:10.5826/dpc.1404a284.